

Philipp Kickingereder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5374510/publications.pdf>

Version: 2024-02-01

88
papers

6,350
citations

81900

39
h-index

69250

77
g-index

90
all docs

90
docs citations

90
times ranked

8561
citing authors

#	ARTICLE	IF	CITATIONS
1	Research Highlight: Use of Generative Images Created with Artificial Intelligence for Brain Tumor Imaging. Korean Journal of Radiology, 2022, 23, 500.	3.4	5
2	Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. Neuro-Oncology Practice, 2022, 9, 310-316.	1.6	7
3	Development and validation of an automated planning tool for navigated lumbosacral pedicle screws using a convolutional neural network. Spine Journal, 2022, 22, 1666-1676.	1.3	4
4	Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment. European Radiology, 2021, 31, 302-313.	4.5	24
5	nnU-Net for Brain Tumor Segmentation. Lecture Notes in Computer Science, 2021, , 118-132.	1.3	148
6	Continuous-Time Deep Glioma Growth Models. Lecture Notes in Computer Science, 2021, , 83-92.	1.3	1
7	Response by Brugnara et al Regarding Article, "The Sense or Futility of Outcome Prediction in Acute Stroke for Endovascular Treatment Decision-Making". Stroke, 2021, 52, e85-e86.	2.0	0
8	Dynamics of cerebral perfusion and oxygenation parameters following endovascular treatment of acute ischemic stroke. Journal of NeuroInterventional Surgery, 2021, , neurintsurg-2020-017163.	3.3	7
9	BIMG-22. DEEP LEARNING SUPER-RESOLUTION MR SPECTROSCOPIC IMAGING TO MAP TUMOR METABOLISM IN MUTANT IDH GLIOMA PATIENTS. Neuro-Oncology Advances, 2021, 3, i5-i6.	0.7	0
10	Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. Journal of Neurochemistry, 2021, 158, 522-538.	3.9	18
11	Improved risk stratification via integration of radiomics and dosiomics features in patients with recurrent high-grade glioma undergoing carbon ion radiotherapy (CIRT).. Journal of Clinical Oncology, 2021, 39, 2043-2043.	1.6	0
12	Optimal thresholds to predict long-term outcome after complete endovascular recanalization in acute anterior ischemic stroke. Journal of NeuroInterventional Surgery, 2021, 13, 1124-1127.	3.3	6
13	Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics, 2021, 11, 9217-9233.	10.0	16
14	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. The Lancet Digital Health, 2021, 3, e784-e794.	12.3	52
15	T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. Neuro-Oncology Advances, 2020, 2, vdaa004.	0.7	27
16	Automated volumetric assessment with artificial neural networks might enable a more accurate assessment of disease burden in patients with multiple sclerosis. European Radiology, 2020, 30, 2356-2364.	4.5	16
17	Multimodal Predictive Modeling of Endovascular Treatment Outcome for Acute Ischemic Stroke Using Machine-Learning. Stroke, 2020, 51, 3541-3551.	2.0	83
18	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine, 2020, 9, 8373-8385.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020, 297, 164-175.	7.3	19
20	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020, 22, 1667-1676.	1.2	9
21	Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. <i>Nature Communications</i> , 2020, 11, 931.	12.8	112
22	Impact of slice thickness on clinical utility of automated Alberta Stroke Program Early Computed Tomography Scores. <i>European Radiology</i> , 2020, 30, 3137-3145.	4.5	12
23	Advanced Physiologic Imaging: Perfusion Theory and Applications. , 2020, , 61-91.		3
24	Radiomics and Deep Learning from Research to Clinical Workflow: Neuro-Oncologic Imaging. <i>Korean Journal of Radiology</i> , 2020, 21, 1126.	3.4	25
25	Automated brain extraction of multisequence MRI using artificial neural networks. <i>Human Brain Mapping</i> , 2019, 40, 4952-4964.	3.6	284
26	Glial Tumors and Primary CNS Lymphoma. , 2019, , 1051-1074.		0
27	Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment. <i>Radiology</i> , 2019, 293, 607-617.	7.3	214
28	Glial Tumors and Primary CNS Lymphoma. , 2019, , 1-25.		1
29	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2019, 20, 728-740.	10.7	271
30	Risk factors of intracranial hemorrhage after mechanical thrombectomy of anterior circulation ischemic stroke. <i>Neuroradiology</i> , 2019, 61, 461-469.	2.2	57
31	NIMG-02. NON-INVASIVE DETECTION OF IDH MUTANT 1p19q NON-CODELETED GLIOMAS USING THE T2-FLAIR MISMATCH SIGN. <i>Neuro-Oncology</i> , 2019, 21, vi161-vi161.	1.2	1
32	NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi163-vi163.	1.2	0
33	Can Virtual Contrast Enhancement in Brain MRI Replace Gadolinium?. <i>Investigative Radiology</i> , 2019, 54, 653-660.	6.2	93
34	Radiomics, Metabolic, and Molecular MRI for Brain Tumors. <i>Seminars in Neurology</i> , 2018, 38, 032-040.	1.4	19
35	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 848-857.	1.2	170
36	Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2018, 20, 557-566.	1.2	24

#	ARTICLE	IF	CITATIONS
37	Increased Delay Between Gadolinium Chelate Administration and T1-Weighted Magnetic Resonance Imaging Acquisition Increases Contrast-Enhancing Tumor Volumes and T1 Intensities in Brain Tumor Patients. <i>Investigative Radiology</i> , 2018, 53, 223-228.	6.2	3
38	ATIM-35. VXM01 PHASE I STUDY IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA – FINAL RESULTS. <i>Neuro-Oncology</i> , 2018, 20, vi9-vi9.	1.2	2
39	Radiomic Machine Learning for Characterization of Prostate Lesions with MRI: Comparison to ADC Values. <i>Radiology</i> , 2018, 289, 128-137.	7.3	162
40	Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. <i>Neuro-Oncology</i> , 2018, 20, 1517-1524.	1.2	36
41	Brain Tumor Segmentation and Radiomics Survival Prediction: Contribution to the BRATS 2017 Challenge. <i>Lecture Notes in Computer Science</i> , 2018, , 287-297.	1.3	244
42	VXM01 phase I study in patients with progressive glioblastoma: Final results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2017-2017.	1.6	87
43	Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 485-494.	4.3	32
44	Downfield –NOE –suppressed amide –CEST –MRI at 7 Tesla provides a unique contrast in human glioblastoma. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 196-208.	3.0	108
45	Pediatric Brain: No Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-weighted MR Images after Consecutive Exposure to a Macrocyclic Gadolinium-based Contrast Agent. <i>Radiology</i> , 2017, 283, 828-836.	7.3	74
46	Prediction of malignancy by a radiomic signature from contrast agent –free diffusion MRI in suspicious breast lesions found on screening mammography.. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 604-616.	3.4	113
47	Accuracy of 1H magnetic resonance spectroscopy for quantification of 2-hydroxyglutarate using linear combination and J-difference editing at 9.4 T. <i>Zeitschrift Fur Medizinische Physik</i> , 2017, 27, 300-309.	1.5	2
48	Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. <i>Journal of Neurosurgery: Pediatrics</i> , 2017, 20, 261-268.	1.3	90
49	Feasibility, Risk Profile and Diagnostic Yield of Stereotactic Biopsy in Children and Young Adults with Brain Lesions. <i>Klinische Padiatrie</i> , 2017, 229, 133-141.	0.6	14
50	Diagnostic challenges in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1588-1598.	1.2	106
51	No Signal Intensity Increase in the Dentate Nucleus on Unenhanced T1-weighted MR Images after More than 20 Serial Injections of Macrocyclic Gadolinium-based Contrast Agents. <i>Radiology</i> , 2017, 282, 699-707.	7.3	98
52	Lateral cephalometric analysis for treatment planning in orthodontics based on MRI compared with radiographs: A feasibility study in children and adolescents. <i>PLoS ONE</i> , 2017, 12, e0174524.	2.5	42
53	Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps. <i>PLoS ONE</i> , 2017, 12, e0174620.	2.5	39
54	Brain Tumor Segmentation Using Large Receptive Field Deep Convolutional Neural Networks. <i>Informatik Aktuell</i> , 2017, , 86-91.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Tumor Infiltration in Enhancing and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology. PLoS ONE, 2017, 12, e0169292.	2.5	113
56	Factors triggering an additional resection and determining residual tumor volume on intraoperative MRI: analysis from a prospective single-center registry of supratentorial gliomas. Neurosurgical Focus, 2016, 40, E4.	2.3	33
57	Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. Radiology, 2016, 281, 907-918.	7.3	236
58	Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response. Clinical Cancer Research, 2016, 22, 5765-5771.	7.0	230
59	Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Investigative Radiology, 2016, 51, 683-690.	6.2	82
60	Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. Radiology, 2016, 280, 880-889.	7.3	345
61	Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Neuro-Oncology, 2016, 18, 1673-1679.	1.2	36
62	Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma. Journal of Neuro-Oncology, 2016, 126, 463-472.	2.9	21
63	MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma. Radiology, 2016, 279, 542-552.	7.3	51
64	Automatic Analysis of Cellularity in Glioblastoma and Correlation with ADC Using Trajectory Analysis and Automatic Nuclei Counting. PLoS ONE, 2016, 11, e0160250.	2.5	35
65	Response. Radiology, 2016, 279, 324-5.	7.3	0
66	IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Scientific Reports, 2015, 5, 16238.	3.3	259
67	High-Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images. Investigative Radiology, 2015, 50, 805-810.	6.2	188
68	Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration. Investigative Radiology, 2015, 50, 743-748.	6.2	151
69	Nuclear Overhauser Enhancement Imaging of Glioblastoma at 7 Tesla: Region Specific Correlation with Apparent Diffusion Coefficient and Histology. PLoS ONE, 2015, 10, e0121220.	2.5	36
70	Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro-Oncology, 2015, 17, 151-159.	1.2	90
71	Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1139-1147.	1.2	89
72	Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology, 2015, 121, 373-380.	2.9	43

#	ARTICLE	IF	CITATIONS
73	Gadolinium Retention in the Dentate Nucleus and Globus Pallidus Is Dependent on the Class of Contrast Agent. <i>Radiology</i> , 2015, 275, 783-791.	7.3	507
74	Asymmetry of Deep Medullary Veins on Susceptibility Weighted MRI in Patients with Acute MCA Stroke Is Associated with Poor Outcome. <i>PLoS ONE</i> , 2015, 10, e0120801.	2.5	49
75	Quantification of Tumor Vessels in Glioblastoma Patients Using Time-of-Flight Angiography at 7 Tesla: A Feasibility Study. <i>PLoS ONE</i> , 2014, 9, e110727.	2.5	30
76	Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation. <i>American Journal of Neuroradiology</i> , 2014, 35, 1503-1508.	2.4	84
77	Primary Central Nervous System Lymphoma and Atypical Glioblastoma: Multiparametric Differentiation by Using Diffusion-, Perfusion-, and Susceptibility-weighted MR Imaging. <i>Radiology</i> , 2014, 272, 843-850.	7.3	137
78	Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases. <i>Journal of Neuro-Oncology</i> , 2014, 120, 615-623.	2.9	34
79	Nuclear Overhauser Enhancement Mediated Chemical Exchange Saturation Transfer Imaging at 7 Tesla in Glioblastoma Patients. <i>PLoS ONE</i> , 2014, 9, e104181.	2.5	62
80	Brain Metastases: Treatment with Stereotactic Iodine-125 Brachytherapy. <i>Tumors of the Central Nervous System</i> , 2014, , 173-186.	0.1	0
81	BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. <i>International Journal of Cancer</i> , 2013, 133, 1624-1630.	5.1	93
82	AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. <i>Acta Neuropathologica</i> , 2013, 126, 757-762.	7.7	88
83	Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region. <i>Neuro-Oncology</i> , 2013, 15, 1721-1731.	1.2	24
84	Diagnostic Value and Safety of Stereotactic Biopsy for Brainstem Tumors. <i>Neurosurgery</i> , 2013, 72, 873-882.	1.1	83
85	Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome. <i>Journal of Neuro-Oncology</i> , 2012, 109, 273-283.	2.9	29
86	Intracavitary brachytherapy using stereotactically applied phosphorus-32 colloid for treatment of cystic craniopharyngiomas in 53 patients. <i>Journal of Neuro-Oncology</i> , 2012, 109, 365-374.	2.9	45
87	Stereotactic biopsy combined with stereotactic 125iodine brachytherapy for diagnosis and treatment of locally recurrent single brain metastases. <i>Journal of Neuro-Oncology</i> , 2011, 105, 109-118.	2.9	28
88	Deep Learning Super-resolution MR Spectroscopic Imaging of Brain Metabolism and Mutant IDH Glioma. <i>Neuro-Oncology Advances</i> , 0, , .	0.7	2